阅读说明：本技术 牛磺罗定在制备抗新型冠状病毒SARS-CoV-2药物中的应用 (Application of taurolidine in preparing medicine for resisting novel coronavirus SARS-CoV-2 ) 是由 苏忠 苏熙尧 严庆文 陈强 晋国庆 于 2020-07-06 设计创作，主要内容包括：本发明涉及一种牛磺罗定在制备抗新型冠状病毒SARS-CoV-2药物中的应用,涉及医药技术领域。本发明首次发现牛磺罗定的新用途,即牛磺罗定在抑制新型冠状病毒SARS-CoV-2、或者在制备抗新型冠状病毒SARS-CoV-2药物中的应用。牛磺罗定对人体的安全性已经得到临床实践的检测,本发明发现了牛磺罗定对新型冠状病毒SARS-CoV-2的明显药效,为抗新型冠状病毒COVID-19提供了强有力的理论基础和实践基础,具有开发价值和推广意义。本发明为新型冠状病毒肺炎的治疗提供了新的途径。(The invention relates to an application of taurolidine in preparing a medicine for resisting novel coronavirus SARS-CoV-2, relating to the technical field of medicines. The invention discovers the new application of the taurolidine for the first time, namely the application of the taurolidine in inhibiting the novel coronavirus SARS-CoV-2 or preparing the medicine for resisting the novel coronavirus SARS-CoV-2. The safety of the taurolidine to human bodies is detected by clinical practice, the invention discovers the obvious drug effect of the taurolidine to the novel coronavirus SARS-CoV-2, provides powerful theoretical basis and practical basis for resisting the novel coronavirus COVID-19, and has development value and popularization significance. The invention provides a new approach for treating the novel coronavirus pneumonia.)

1. Application of taurolidine in inhibiting novel coronavirus SARS-CoV-2 is provided.

2. An application of taurolidine in preparing the medicines for treating the SARS-CoV-2 caused by coronavirus is disclosed.

3. The use of claim 2, wherein the taurolidine is in the form of an injection, infusion, tablet, or capsule.

4. The use of claim 3, wherein said taurolidine is in the form of an infusion solution.

Technical Field

The invention relates to the technical field of medicines, in particular to application of taurolidine in preparing a medicine for resisting novel coronavirus SARS-CoV-2.

Background

The novel coronavirus pneumonia (Corona Virus Disease 2019, COVID-19) is called new coronavirus pneumonia for short, and the world health organization is named as '2019 coronavirus Disease'. It is a contagious disease mainly characterized by fever, dry cough, hypodynamia and certain lethality rate, which are caused by a novel coronavirus SARS-CoV-2. Until now, no specific medicine for treating the novel coronavirus pneumonia exists.

Chinese patents CN101274921A and CN101285813A disclose that Taurolidine (Taurolidine) has a chemical name: 4,4 ' -methylenebis- (tetrahydro-2H-1, 2, 4-thiadiazine) -1,1,1 ', 1 ' tetraoxide with the molecular formula C₇H₁₆N₄O₄S₂The molecular weight is: 284.348, is white or white-like crystalline powder, and has the following chemical formula:

can be synthesized by the following synthetic route:

taurolidine is a broad spectrum antibacterial, antifungal and antiendotoxic drug. Is mainly used for preventing the junior symptoms of patients suffering from various blood stream infections related to the catheter. It can also be used for treating otitis, pleuropneumonia, osteomyelitis, dermatitis, periodontitis, gingivitis, acne, and ulcer. However, no use of taurolidine for the novel coronavirus SARS-CoV-2 has been found so far.

Disclosure of Invention

The invention aims to provide a new application of taurolidine, namely the application of taurolidine in inhibiting novel coronavirus SARS-CoV-2 or preparing medicaments for resisting novel coronavirus SARS-CoV-2.

In the technical scheme, the taurolidine is prepared into injection, infusion solution, tablets, capsules and the like, and the infusion solution is preferred.

The invention has the beneficial effects that:

the invention discovers the new application of the taurolidine for the first time, namely the application of the taurolidine in inhibiting the novel coronavirus SARS-CoV-2 or preparing the medicine for resisting the novel coronavirus SARS-CoV-2. The safety of taurolidine to human body has been tested by clinical practice, the invention discovers the obvious drug effect of taurolidine to novel coronavirus SARS-CoV-2, provides powerful theoretical basis and practical basis for resisting novel coronavirus SARS-CoV-2, and has development value and popularization significance. The invention provides a new approach for treating the novel coronavirus pneumonia.

Detailed Description

In order that the nature of the invention may be better understood, the invention will now be described in further detail with reference to specific examples, which are intended to be illustrative of the invention and not to be limiting of the invention. Next, the inhibitory effect of taurolidine on the novel coronavirus SARS-CoV-2 was examined at the cellular level.

Firstly, experimental materials:

1.1 cells 293T cells from the military veterinary institute virology laboratory;

1.2 strain SARS-CoV-2 virus, from the virology research laboratory of the military veterinary institute;

1.3 reagent DMEM medium, 0.25% trypsin, FBS, PBS (FH ═ 7.0);

1.4 instrument consumable pipettor and supporting suction head, 1.5mL centrifuging tube, ice box, ice machine, biological safety cabinet, carbon dioxide incubator.

II, an experimental method:

2.1 the cell culture recovers 293T cells, continuously transmits the 293T cells for three generations, and is used for experimental study after the cells grow well;

2.2 Virus culture the preserved virus liquid is placed on ice to be slowly melted and then inoculated to a single layer of 293T cells (no more than 24 hours), the culture is continued for 72 to 96 hours, and the virus liquid is harvested according to the cytopathic state. And determining the virus content as TCID₅₀The unit of calculation is/100. mu.L.

2.3 taurolidine inhibition

Drugs are mixed with virus and simultaneously inoculated into cells: the 293T cells with good growth condition are digested by pancreatin, the cell content is calculated, and the cells are inoculated in 96 holesPlate, each hole 10⁵Individual cells, seeded within 12 hours and in monolayer state for study of drug action. Inoculation virus content of 200 TCIDs₅₀The SARS-CoV-2 virus and taurolidine are mixed and immediately inoculated into a paved 96-well plate, and the 2 percent taurolidine solution and the drug dosage are 50 mu L, 25 mu L, 12.5 mu L, 7.5 mu L and 3.75 mu L. Setting blank cell control and taurolidine cytotoxicity control, and repeating for 3 times;

placing the inoculated cell plate at 37 ℃ and CO₂In the incubator, the culture was continued and the cytopathic effect was observed.

Third, experimental results

According to the above experimental method, CO is maintained at 37 deg.C₂The cell state was observed in the incubator for 72 hours, and the cell state was good and no cytopathic effect was observed under the microscope in the case of 50. mu.L and 25. mu.L of the drug as the inoculum dose. The cytopathic effect of 12.5. mu.L, 7.5. mu.L and 3.75. mu.L appeared to different degrees, and the inoculation dose of 3.75. mu.L was used as the group and 200TCID was used₅₀The cytopathic effect was not different.

Fourthly, judging the result

Based on the above experimental results, it was determined that 200TCID was completely inhibited when the drug was administered in a dose of 50. mu.L or 25. mu.L₅₀200TCID was not completely inhibited by 12.5. mu.L, 7.5. mu.L of the inoculum dose₅₀Virus-infected cells failed to inhibit 200TCID at an inoculum dose of 3.75. mu.L₅₀The virus infects the cells.

It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.